COVID-19 Clinical Trial
Official title:
An Adaptive, Multicenter, Randomized, Open-label, Comparative Clinical Study to Assess Efficacy and Safety of Favipiravir in Hospitalized Patients With COVID-19
Verified date | June 2020 |
Source | Chromis LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study is Phase II/III and consists of pilot and pivotal stages. The objective of the pilot stage is to conduct a preliminary assessment of the efficacy and safety of Favipiravir, and to select the optimal dosing regimen to study during the pivotal stage. The objective of the pivotal stage is to assess the efficacy and safety of Favipiravir compared with the Standard of care (SOC) in hospitalized patients with moderate to severe COVID-19 pneumonia.
Status | Active, not recruiting |
Enrollment | 330 |
Est. completion date | July 2020 |
Est. primary completion date | July 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Signed Patient Information Sheet and Informed Consent form to participate in the study. 2. Men and women aged 18 years and older. 3. Patients hospitalized with a diagnosis of COVID-19. 4. The diagnosis of COVID-19 was confirmed by positive reverse transcription polymerase chain reaction (RT-PCR) test for SARS-CoV-2, performed no earlier than 7 days before hospitalization or at screening. 5. Moderate severity of COVID-19 with pneumonia with at least 1 of the following symptoms: - Fever above 38 °C; - Cough; - Shortness of breath during physical exertion; - C reactive protein (CRP) of blood serum > 10 mg/l; - SpO2 < 95% 6. The capability of oral drug administration. 7. The patients' consent to use adequate contraception methods during the study (condom with spermicide) and for 3 months following completion. Exclusion Criteria: 1. Severe type of disease, with at least one of the following criteria: - Frequency of breath > 35 per minute, which does not decrease after the body temperature drops to normal or subfebrile values; - Blood oxygen saturation (SpO2) < 90% at rest; - Partial pressure of oxygen in arterial blood (PaO2) < 60 mm Hg; - Oxygenation index (RaO2/FiO2) = 200 mm Hg; - Partial pressure of CO2 in arterial blood (PaCO2) < 60 mm Hg; - Septic shock. 2. Patients treated with lopinavir/ritonavir, ribavirin, arbidol, chloroquine, hydroxychloroquine, mefloquine, favipiravir within 7 days prior to screening. 3. Severe cardiovascular diseases currently or 6 months prior to randomization, including: New York Heart Association (NYHA) Class III or IV chronic heart failure, clinically significant ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation), unstable angina, myocardial infarction, heart and coronary vessel surgery, significant valvular heart disease, uncontrolled arterial hypertension with systolic blood pressure > 180 mm Hg and diastolic blood pressure > 110 mm Hg, pulmonary embolism or deep vein thrombosis. 4. Severe chronic renal impairment (GFR < 30 ml / min) or continuous renal replacement therapy, hemodialysis or peritoneal dialysis. 5. A history of cirrhosis or an increase in alanine aminotransferase (ALT) and / or aspartate aminotransferase (AST) > 5 times × upper limit of normal (ULN). 6. Severe diseases of the central nervous system, including seizures in history or conditions that may lead to their development; stroke or transient ischemic attack within 12 months prior to screening; head injuries or loss of consciousness within 12 months prior to screening; a brain tumor. 7. Significant uncontrolled concomitant disease, e.g. neurological, renal, hepatic, endocrinological or gastrointestinal disorder which according to the Investigator, could prevent the patient from participating in the study 8. Malignancies that require chemotherapy within 6 months prior to screening. 9. Known HIV infection 10. Hypersensitivity to any component of the study drug. 11. Participation in other clinical studies or taking other study drugs within 28 days prior to screening. 12. Pregnant or lactating women or women planning to get pregnant during the clinical study; women of child-bearing potential (including non-sterilized by surgical means and during the post-menopause period less than 2 years) who do not use adequate contraception methods. 13. Inability to read or write, unwillingness to understand and follow procedures of study protocol, as well as any other concomitant medical or serious mental conditions that make the patient unfit to participate in the study, limit the legality of obtaining informed consent or can affect patient's ability to participate in the study. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Republican Clinical Hospital | Makhachkala | |
Russian Federation | "K+31" Clinic | Moscow | |
Russian Federation | "Khaven" Llc | Moscow | |
Russian Federation | Central Clinical Hospital with Polyclinic | Moscow | |
Russian Federation | Central Research Institute of Epidemiology | Moscow | |
Russian Federation | City Clinical Hospital n.a. O.M. Filatov | Moscow | |
Russian Federation | City Clinical Hospital named after S.S. Yudin | Moscow | |
Russian Federation | City Clinical Hospital No. 24 | Moscow | |
Russian Federation | City Clinical Hospital No. 51 | Moscow | |
Russian Federation | First Moscow State Medical University n.a. I.M. Sechenov | Moscow | |
Russian Federation | Moscow State University n.a. M. V. Lomonosov | Moscow | |
Russian Federation | National Medical and Surgical Center named after N.I. Pirogov | Moscow | |
Russian Federation | City Hospital ? 33 of the Leninsky region of Nizhny Novgorod | Nizhny Novgorod | |
Russian Federation | Infectious clinical hospital No.2 of Nizhny Novgorod | Nizhny Novgorod | |
Russian Federation | Ryazan State Medical University named after I.P. Pavlov | Ryazan | |
Russian Federation | Military Medical Academy named after S.M. Kirova | Saint Petersburg | |
Russian Federation | Saratov State Medical University named after V.I. Razumovsky | Saratov | |
Russian Federation | Clinical hospital No.1 | Smolensk | |
Russian Federation | Regional Clinic Hospital | Tver | |
Russian Federation | Bashkir State Medical University | Ufa | |
Russian Federation | Yakutsk City Clinical Hospital | Yakutsk | |
Russian Federation | Yaroslavl Regional Clinical Hospital for War Veterans | Yaroslavl |
Lead Sponsor | Collaborator |
---|---|
Chromis LLC | Chemical Diversity Research Institute |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of viral elimination by Day 10 [pilot stage, dose selection] | Percent of patients with undetectable SARS-CoV-2 RNA level on Day 10 | 10 Days | |
Primary | Time to viral elimination [pivotal stage] | Median time to reach undetectable SARS-CoV-2 RNA level | 28 Days | |
Primary | Time to clinical improvement [pivotal stage] | Median time reach clinical improvement (2 points of the Ordinal Scale for Clinical Improvement) or discharge from the hospital | 28 Days | |
Secondary | Rate of viral elimination | Percent of patients with undetectable SARS-CoV-2 RNA level | Days 3, 5, 7, 9, and 11 | |
Secondary | Time to normalization of clinical symptoms | Median time [days] to reach normal levels of clinical indicators (body temperature, SpO2, breathing rate) | 28 Days | |
Secondary | Duration of oxygen therapy | Mean duration of oxygen therapy [days] | 28 Days | |
Secondary | Change in the level of lung damage according to CT | Change of lung damage level according to CT comparing to baseline [% of patients] | Days 15, 22, and 29 | |
Secondary | Rate of transfer to the intensive care unit | Percent of patients transferred to the intensive care unit [% of patients] | 28 days | |
Secondary | Rate of the use of non-invasive lung ventilation | Percent of patients undergoing non-invasive lung ventilation [% of patients] | 28 days | |
Secondary | Rate of the use of mechanical ventilation | Percent of patients undergoing mechanical ventilation [% of patients] | 28 days | |
Secondary | Mortality | Percent of patients died within 28-days period [% of patients] | 28 days | |
Secondary | Peak plasma concentration (Cmax) | Determination of Cmax [ng/ml] | Day 1 | |
Secondary | Time to peak plasma concentration (Tmax) | Determination of Tmax [h] | Day 1 | |
Secondary | Area under the plasma concentration versus time curve (AUC0-t) | Determination of AUC0-t [ng*h/ml] | 10 days | |
Secondary | Trough plasma concentration (Ctrough) | Determination of Ctrough [ng/ml] | 10 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|